Universal Ibogaine (TSXV:IBO) Cash-to-Debt : 0.13 (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Universal Ibogaine's cash to debt ratio for the quarter that ended in Jan. 2024 was 0.13.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Universal Ibogaine couldn't pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Universal Ibogaine's Cash-to-Debt or its related term are showing as below:

TSXV:IBO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 2.05 Max: No Debt
Current: 0.13

During the past 7 years, Universal Ibogaine's highest Cash to Debt Ratio was No Debt. The lowest was 0.06. And the median was 2.05.

TSXV:IBO's Cash-to-Debt is ranked worse than
93.57% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs TSXV:IBO: 0.13

Universal Ibogaine Cash-to-Debt Historical Data

The historical data trend for Universal Ibogaine's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Universal Ibogaine Cash-to-Debt Chart

Universal Ibogaine Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Jul22

Jul23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

2.05

0.42

0.11

Universal Ibogaine Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															0.08	0.13	0.11	0.06	0.13

Competitive Comparison of Universal Ibogaine's Cash-to-Debt

For the Biotechnology subindustry, Universal Ibogaine's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Cash-to-Debt falls into.

Universal Ibogaine Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Universal Ibogaine's Cash to Debt Ratio for the fiscal year that ended in Jul. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.313	/	(1.815	+	0.962)
	=	0.11

Universal Ibogaine's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.365	/	(0.131	+	2.666)
	=	0.13

Universal Ibogaine (TSXV:IBO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Universal Ibogaine Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Universal Ibogaine (TSXV:IBO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

IBOGF:USA JC4:Germany

Address

400 3rd Avenue South west, Suite 1470, Calgary, AB, CAN, T2P 4H2

Website

https://www.universalibogaine.com

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Universal Ibogaine (TSXV:IBO) Headlines

No Headlines